← FDA DRUG APPROVALS

FDA ANDA · ANDA207170

TIZANIDINE HYDROCHLORIDE

Sponsor: PH HEALTH

APPLICATION
ANDA207170
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-26
LATEST ACTION
2017-01-26
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TIZANIDINE HYDROCHLORIDEDiscontinued
TIZANIDINE HYDROCHLORIDE EQ 2MG BASE · TABLET · ORAL
TIZANIDINE HYDROCHLORIDEDiscontinued
TIZANIDINE HYDROCHLORIDE EQ 4MG BASE · TABLET · ORAL

Approval history

2017-01-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →